Abstract
Our understanding of the complex signaling neurophysiology of the central nervous system has facilitated the exploration of potential novel receptor-ligand system targets for disorders of this most complex organ. In recent years, many relatively neglected receptor-ligand systems have been re-evaluated with respect to their ability to potently modulate discrete tracts in the central nervous system. One such system is the tachykinin (previously neurokinin) system. The multiple heptahelical G protein-coupled receptors and neuropeptide ligands that comprise this system may be significantly involved in more central nervous systems actions than previously thought, including sleep disorders, amyotrophic lateral sclerosis, Alzheimers disease and Machado-Joseph disease. The development of our understanding of the role of the tachykinin receptor-ligand system in higher order central functions is likely to allow the creation of more specific and selective tachykinin-related neurotherapeutics.
Keywords: Central neurological disorders, substance P, neurokinin A, neurokinin B, neurotherapeutics, receptor-ligand systems, tachykinin
CNS & Neurological Disorders - Drug Targets
Title: The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
Volume: 9 Issue: 5
Author(s): Nick Pantaleo, Wayne Chadwick, Sung-Soo Park, Liyun Wang, Yu Zhou, Bronwen Martin and Stuart Maudsley
Affiliation:
Keywords: Central neurological disorders, substance P, neurokinin A, neurokinin B, neurotherapeutics, receptor-ligand systems, tachykinin
Abstract: Our understanding of the complex signaling neurophysiology of the central nervous system has facilitated the exploration of potential novel receptor-ligand system targets for disorders of this most complex organ. In recent years, many relatively neglected receptor-ligand systems have been re-evaluated with respect to their ability to potently modulate discrete tracts in the central nervous system. One such system is the tachykinin (previously neurokinin) system. The multiple heptahelical G protein-coupled receptors and neuropeptide ligands that comprise this system may be significantly involved in more central nervous systems actions than previously thought, including sleep disorders, amyotrophic lateral sclerosis, Alzheimers disease and Machado-Joseph disease. The development of our understanding of the role of the tachykinin receptor-ligand system in higher order central functions is likely to allow the creation of more specific and selective tachykinin-related neurotherapeutics.
Export Options
About this article
Cite this article as:
Pantaleo Nick, Chadwick Wayne, Park Sung-Soo, Wang Liyun, Zhou Yu, Martin Bronwen and Maudsley Stuart, The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361504
DOI https://dx.doi.org/10.2174/187152710793361504 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evidence that Ingested Aluminum Additives Contained in Processed Foods and Alum-Treated Drinking Water are a Major Risk Factor for Alzheimers Disease
Current Inorganic Chemistry (Discontinued) Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Snake Venom: From Deadly Toxins to Life-saving Therapeutics
Current Medicinal Chemistry Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Protein Cysteine Modifications: (1) Medicinal Chemistry for Proteomics
Current Medicinal Chemistry Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry